An open label, 3-arm, randomised phase II study to compare the safety and efficacy of ponatinib in combination with either chemotherapy or blinatumomab with imatinib plus chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome-positive (Ph+ or BCR-ABL+) acute lymphoblastic leukemia (ALL)
Principal investigator: Kimmo Porkka
HUS Helsinki University Hospital, Comprehensive Cancer Center
